Nature Communications (Feb 2016)

Self-renewal of CD133hi cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer

  • Pasquale Sansone,
  • Claudio Ceccarelli,
  • Marjan Berishaj,
  • Qing Chang,
  • Vinagolu K. Rajasekhar,
  • Fabiana Perna,
  • Robert L. Bowman,
  • Michele Vidone,
  • Laura Daly,
  • Jennifer Nnoli,
  • Donatella Santini,
  • Mario Taffurelli,
  • Natalie N. C. Shih,
  • Michael Feldman,
  • Jun J. Mao,
  • Christopher Colameco ,
  • Jinbo Chen,
  • Angela DeMichele,
  • Nicola Fabbri,
  • John H. Healey,
  • Monica Cricca,
  • Giuseppe Gasparre,
  • David Lyden,
  • Massimiliano Bonafé,
  • Jacqueline Bromberg

DOI
https://doi.org/10.1038/ncomms10442
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 10

Abstract

Read online

ER+ breast cancer patients treated with endocrine therapies often acquire resistance and develop metastasis. In this study, the authors demonstrate that endocrine therapies can promote the self-renewal of CD133hi/ERlodrug resistant cells with metastatic potential driven through the IL6-Notch3 axis activation.